Loading...
•
Sep 30, 2023
Ironwood Pharmaceuticals Q3 2023 Earnings Report
Reported third quarter 2023 results, featuring growth in LINZESS prescription demand and U.S. net sales, alongside positive data from the STARS Nutrition study and progress in pipeline development.
Key Takeaways
Ironwood Pharmaceuticals reported its third quarter 2023 results, highlighting an 8% year-over-year increase in LINZESS EUTRx prescription demand and a 7% year-over-year increase in LINZESS U.S. net sales, which reached $279 million. The company also announced positive final data from the STARS Nutrition study and anticipates topline data for the Phase II study of CNP-104 in Q3 2024.
LINZESS EUTRx prescription demand grew by 8% year-over-year.
LINZESS U.S. net sales increased by 7% year-over-year, totaling $279 million.
Positive final data was reported from the STARS Nutrition Phase II study of apraglutide in short bowel syndrome with intestinal failure.
Topline data for the Phase II study of CNP-104 in primary biliary cholangitis is expected in the third quarter of 2024.
Forward Guidance
Ironwood maintains its full year 2023 guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...